Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stryker Makes Big Investment In Spine Surgery With $1.4Bn K2M Acquisition

Executive Summary

The orthopedics giant will pay $27.50 per share for the Leesburg, Va., company, representing a 27% premium over K2M's average closing price over the last 90 days. The terms of the deal also call for K2M CEO to take over as president of Stryker's Spine business, displacing current president Bradley Paddock.

You may also be interested in...



Stryker Goes Shoulder To Shoulder With Wright Medical In $4Bn Takeover

Stryker is acquiring rival Wright Medical in a $4bn deal catapulting the company to a top position in the trauma and extremities market. The agreement, announced on 4 November, is Stryker’s biggest acquisition this year.

Stryker’s Mako Robot Continues To Bite Orthopedic Surgery Competition

The company said it expected Mako to continue to drive market share gains in hip and knee surgery. Stryker sold 51 Mako robotic orthopedic surgery systems in the third quarter, bringing the total installed base to 772.

2018 Earnings Spotlight: Stryker And Nuvasive Lead The Ortho Pack In 2018

Reported sales and earnings from the big publicly traded orthopedics device companies showed mostly slow growth in 2018, but NuVasive and Stryker reported high single-digit growth while, Smith & Nephew grew in the low single-digits, fueling reports that Smith & Nephew may try to buy NuVasive.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

MT123208

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel